Drug Type Gene therapy |
Synonyms hVEGF-A, SB 509, SB-509 |
Target |
Action stimulants, inducers |
Mechanism VEGF-A stimulants(Vascular endothelial growth factor A stimulants), Angiogenesis inducers, Gene transference(Gene transference) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Macular Edema | Phase 3 | United States | 01 Jul 2009 | |
Macular Edema | Phase 3 | Canada | 01 Jul 2009 | |
Macular Edema | Phase 3 | Colombia | 01 Jul 2009 | |
Macular Edema | Phase 3 | India | 01 Jul 2009 | |
Macular Edema | Phase 3 | Israel | 01 Jul 2009 | |
Amyotrophic Lateral Sclerosis | Phase 2 | United States | 01 Sep 2008 | |
Diabetes Mellitus, Type 1 | Phase 2 | United States | 01 Nov 2006 | |
Diabetes Mellitus, Type 1 | Phase 2 | Mexico | 01 Nov 2006 | |
Diabetes Mellitus, Type 2 | Phase 2 | United States | 01 Nov 2006 | |
Diabetes Mellitus, Type 2 | Phase 2 | Mexico | 01 Nov 2006 |